---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/35608318.md"
description: "$Arcturus Therapeutics(ARCT.US)https://mp.weixin.qq.com/s/C-FJ2P9SyDpT5Kzkbirwrw   In-depth analysis of the root cause of ARCT's misjudgment, the argument of ARCT032 trial failure is invalid - independent thinking and in-depth analysis are the keys to successful investment. Recently, ARCT (Arcturus Therapeutics) stock price experienced a significant drop, with a single-day decline of up to 60%. We pointed out in a previous article that this was clearly a misjudgment, and the root cause of this misjudgment lies in the market interpreting the ARCT032 Phase II interim data as a failure, leading to unnecessary panic."
datetime: "2025-10-26T12:29:01.000Z"
locales:
  - [en](https://longbridge.com/en/topics/35608318.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/35608318.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/35608318.md)
author: "[砺身济世](https://longbridge.com/en/profiles/19728405.md)"
---

# $Arcturus Therapeutics(ARCT.US)https://mp.weixin.q…


### Related Stocks

- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)